2024-11-05 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO)**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. 

**Cumulative Returns:**
* JNJ: 33.48%
* VOO: 131.78%

**Divergence:** 
* **Current Divergence:** -98.3% 
* **Relative Divergence:** 6.23% (This means JNJ is performing in the 6.23rd percentile of its historical performance compared to VOO).

**Alpha and Beta Analysis:**
* JNJ has generally shown **low to moderate alpha** (excess return compared to the benchmark), indicating it has outperformed VOO in certain periods, but not consistently.
* The **beta** is consistently below 1, suggesting lower volatility than the market (VOO). This means JNJ's price is less sensitive to market fluctuations.

**2. Recent Price Movement:**

* **Last Market Price:** $158.67
* **5-Day Moving Average:** $160.46
* **20-Day Moving Average:** $162.02
* **60-Day Moving Average:** $162.72

The price is currently below all three moving averages, suggesting **short-term weakness**. However, the difference is relatively small, indicating the price is not too far off its recent trends.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 45.82 (Neutral) - This suggests that the stock is neither overbought nor oversold, indicating potential for both upward and downward movement.
* **PPO (Percentage Price Oscillator):** -0.23 (Bearish) - A negative PPO suggests a downward trend, although the small value (-0.23) indicates a weak bearish signal.
* **Delta_Previous_Relative_Divergence:** 0.89 (+) (Short-term Upward Trend) - This signifies a recent positive change in the relative performance of JNJ compared to VOO.

**4. Recent Earnings and Outlook:**

* **Latest Earnings:** $1.12 EPS and $22.47B Revenue (2024-10-23)
* **Analyst Estimates:** No specific analyst estimates for the latest earnings were provided. 
* **Past Earnings:** The company consistently delivered revenues above $20 billion in recent quarters, with a slight dip in the last quarter.

**5. Financial Information:**

* **Revenue and Profitability:** Consistently high revenue and profit margins above 68%, demonstrating JNJ's strong financial position.
* **Capital and Profitability:** High equity and a generally stable ROE, indicating good financial health and consistent returns on investment.

**6. News and Recent Issues:**

* **Recent Earnings News:** You'll need to refer to sources like Shacknews and financial news websites to get the latest earnings news and analyst reactions. 
* **Market Outlook:**  You should search financial websites like FINBOLD for recent market outlooks, analyst opinions, and performance highlights of JNJ.

**7. Overall Analysis:**

JNJ is a large-cap, established company with a strong financial position, consistently high revenue and profit margins, and a history of stable returns. However, the stock has underperformed the S&P 500 in recent years, reflecting its slower growth compared to the broader market. Current technical indicators suggest short-term weakness, but the stock's long-term prospects remain positive.

**8. English Report Summary:**

Johnson & Johnson is a well-established company with a strong financial position and history of stable returns. While it has underperformed the S&P 500 in recent years, recent technical indicators suggest short-term weakness but long-term prospects remain positive. However, the stock's slower growth compared to the broader market, is a concern. 
